860798-06-7

Upstream product

• 56341-37-8 6-chloro-2-oxindole 
• 587-04-2 m-Chlorobenzaldehyde 

Downstream Products

• 897365-77-4 C₃₇H₃₄Cl₂N₂O₃ 
• 897365-78-5 (2'R,3'S,4'R,5'R)-6-Chloro-4'-(3-chloro-phenyl)-2'-(2,2-dimethyl-propyl)-1'-((1R,2S)-2-hydroxy-1,2-diphenyl-ethyl)-2-oxo-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (2-morpholin-4-yl-ethyl)-amide 
• 860797-93-9 (1''R,2''S,2'R,3'R,3S,4'R)-6-chloro-4'-(3-chlorophenyl)-1'-(2-hydroxy-1,2-diphenylethyl)-2'-isobutyl-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid dimethylamide 
• 860797-96-2 (1''R,2''S,2'R,3'R,3S,4'R)-6-chloro-4'-(3-chlorophenyl)-1'-(2-hydroxy-1,2-diphenylethyl)-2'-propyl-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid dimethylamide 
• 860797-95-1 (1''R,2''S,2'R,3'R,3S,4'R)-6-chloro-4'-(3-chlorophenyl)-2'-(2,2-dimethylpropyl)-1'-(2-hydroxy-1,2-diphenylethyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid dimethylamide 
• 860797-97-3 (1''R,2''S,2'R,3'R,3S,4'R)-6-chloro-4'-(3-chlorophenyl)-1'-(2-hydroxy-1,2-diphenylethyl)-2'-(3-methylbutyl)-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid dimethylamide 
• 949026-52-2 E/Z-6-chloro-3-(3-chloro-benzylidene)-2-oxo-2,3-dihydro-indole-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Discovery of Novel Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction

Scaffold modification based on Wang's pioneering MDM2-p53 inhibitors led to novel, chemically stable spiro-oxindole compounds bearing a spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one scaffold that are not prone to epimerization as observed for the initial spiro[3H-indole-3,3′-pyrrolidin]-2(1H)-one scaffold. Further structure-based optimization inspired by natural product architectures led to a complex fused ring system ideally suited to bind to the MDM2 protein and to interrupt its protein-protein interaction (PPI) with TP53. The compounds are highly selective and show in vivo efficacy in a SJSA-1 xenograft model even when given as a single dose as demonstrated for 4-[(3S,3′S,3′aS,5′R,6′aS)-6-chloro-3′-(3-chloro-2-fluorophenyl)-1′-(cyclopropylmethyl)-2-oxo-1,2,3′,3′a,4′,5′,6′,6′a-octahydro-1′H-spiro[indole-3,2′-pyrrolo[3,2-b]pyrrole]-5′-yl]benzoic acid (BI-0252).

Spiroindolinone Derivatives

There are provided compounds of the formula or a pharmaceutically acceptable salt or ester thereof wherein X, Y, R1, R2 are as herein described. The compounds have utility as antiproliferative agents, especially, as anticancer agents

SPIROINDOLINONE DERIVATIVES

There are provided spiroindolinone derivatives of the formula and pharmaceutically acceptable salts and esters thereof wherein R1, R2, R3, R4 and R are as herein described. The compounds exhibit anticancer activity.

SPIROINDOLINONE DERIVATIVES

The present invention relates to spiroindolinone derivatives of the formula and their enantiomers and pharmaceutically acceptable salts and esters thereof wherein R1, R2, R3, R4, R5, R6, R7 and R8, are as herein described.

SMALL MOLECULE INHIBITORS OF MDM2 AND USES THEREOF

The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sens